Li Min-Ju, Huang Yong, Tang Da-Xing, Zhou Yin-Bao, Tang Hong-Feng, Liang Jian-Feng
Department of Pediatric Surgery, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):791-5.
To improve prognosis of the patients with advanced Wilms' tumor, the authors compared different therapeutic strategies including preoperative transcatheter arterial chemoembolization (TACE), conventional preoperative chemotherapy and initial surgery.
Sixty-two patients aged from 5 months to 10 years (mean 3.2 years) were identified from medical records to have histologically confirmed advanced Wilms' tumor during the period from January 1993 to December 2002. The criteria for choice were huge tumor size with a volume more than 550 ml or the mass extending beyond the midline, involvement of vital structures, inferior vena cava invasion, distal metastasis or bilateral Wilms' tumor judged by imaging examination. All cases were divided into 3 groups according to the treatment received: 31 cases in group TACE received preoperative transcatheter arterial chemoembolization with Lipiodol-Epirubicin (EPI)-Vincristine emulsion. One week after TACE, systemic chemotherapy with Actinomycin D (ACTD) was administered and tumor resected at two weeks after TACE. 20 cases in group PC received conventional preoperative chemotherapy with VCR, ACTD plus EPI for 4-5 weeks, and 11 cases in group IS underwent initial surgery. Postoperative treatment for all patients was based on the postoperative staging and tumor histology.
In the patients treated with TACE, no drug-induced complications such as cardiotoxicity, nephrotoxicity, hepatic dysfunction or bone marrow suppression were observed except for mild fever due to tumor necrosis. The percentages of tumor size shrinkage were 32.4% and 20.3% in group TACE and group PC, respectively (P < 0.05). Complete surgical removal of the tumor was achieved in 27 patients (87.1%) in group TACE, significantly higher in comparison with 14 in group PC (70.0%, P < 0.05) and 2 in group IS (18.2%, P < 0.01). Event-free survival (EFS) at 2 years was 87.1% (27/ 31), 60.0% (12/20) and 18.2% (2/11), respectivrely. EFS at 4 years was 84.6% (11/13), 56.3% (9/16 ) and 18.2% (2/11) in groups TACE, PC and IS, respectively.
The present study has shown that both preoperative TACE and conventional preoperative chemotherapy can be applied to the patients with advanced Wilms' tumor who are not candidates for immediately surgical resection. The survival is significantly increased in the patients undergoing preoperativeTACE when compared with conventional preoperative chemotherapy and initial surgery.
为改善晚期肾母细胞瘤患者的预后,作者比较了不同的治疗策略,包括术前经导管动脉化疗栓塞术(TACE)、传统术前化疗和直接手术。
从1993年1月至2002年12月的病历中确定62例年龄在5个月至10岁(平均3.2岁)、经组织学确诊为晚期肾母细胞瘤的患者。选择标准为肿瘤体积巨大(超过550 ml)或肿块超过中线、累及重要结构、侵犯下腔静脉、远处转移或经影像学检查判断为双侧肾母细胞瘤。所有病例根据接受的治疗分为3组:TACE组31例,接受碘油-表柔比星(EPI)-长春新碱乳剂术前经导管动脉化疗栓塞术。TACE术后1周,给予放线菌素D(ACTD)全身化疗,并在TACE术后2周切除肿瘤。PC组20例接受VCR、ACTD加EPI的传统术前化疗4 - 5周,IS组11例接受直接手术。所有患者术后治疗均基于术后分期和肿瘤组织学。
在接受TACE治疗的患者中,除因肿瘤坏死引起的低热外,未观察到心脏毒性、肾毒性、肝功能障碍或骨髓抑制等药物诱导的并发症。TACE组和PC组肿瘤大小缩小百分比分别为32.4%和20.3%(P < 0.05)。TACE组27例患者(87.1%)实现了肿瘤的完整手术切除,与PC组的14例(70.0%,P < 0.05)和IS组的2例(18.2%,P < 0.01)相比显著更高。2年无事件生存率(EFS)分别为87.1%(27/31)、60.0%(12/20)和18.2%(2/11)。TACE组、PC组和IS组4年EFS分别为84.6%(11/13)、56.3%(9/16)和18.2%(2/11)。
本研究表明,术前TACE和传统术前化疗均可应用于不适合立即手术切除的晚期肾母细胞瘤患者。与传统术前化疗和直接手术相比,接受术前TACE治疗的患者生存率显著提高。